Highlights from the Growth Sector

A Significant Milestone in Diagnostics

Gemina Labs is making waves in point-of-care diagnostics with innovative advancements that are set to revolutionize lateral flow testing. CEO Brian Firth details the company’s significant milestone of securing their first license agreement with a major global diagnostics player, signaling a promising future with a robust pipeline of similar deals on the horizon. This achievement not only validates Gemina’s cutting-edge technology but also positions the company as an industry leader.

Advancing Lateral Flow Testing Technology

The core innovation that sets Gemina Labs apart lies in their proprietary chemistry, which enhances the sensitivity and reliability of lateral flow tests. Traditional tests suffer from inefficiencies due to the random orientation of antibodies on the test line. Gemina’s technology ensures that a higher percentage of antibodies are properly aligned to capture antigens, significantly improving test sensitivity. This advancement is not limited to COVID-19 diagnostics but extends across a broad spectrum of applications, from pregnancy tests to cancer and cardiology screenings.

Market Potential and Strategic Positioning

With the global in-vitro diagnostics market valued at $97 billion, and a substantial $43 billion in the point-of-care segment, Gemina Labs is strategically positioned to make a considerable impact. The company’s focus on expanding their technology to various sample types and securing further license agreements underscores their commitment to innovation and leadership in diagnostics.

Looking Ahead: Expansion and Fundraising

Gemina Labs is poised for significant growth as they embark on raising funds for a new protein production facility. This initiative is aimed at supporting the anticipated demand from upcoming license agreements and further development of their breakthrough technologies. By securing additional funding and expanding their production capabilities, Gemina Labs is well-positioned to continue its trajectory as a pivotal player in the advancement of medical diagnostics, with several promising developments on the horizon.

Gemina Labs stands as a trailblazer in the field of point-of-care diagnostics, driven by a steadfast commitment to reshaping healthcare delivery. Under Brian Firth’s leadership, the company has demonstrated a remarkable dedication to leveraging technology, accessibility, and impact for the betterment of global health outcomes. As Gemina Labs continues to forge ahead on its path of growth and discovery, its influence promises to be profound, heralding a new era of accessible, efficient, and lifesaving diagnostics for communities worldwide.

To continue to follow Gemina Labs’ groundbreaking innovations in diagnostics, submit your name and email below.

Disclosure & Disclaimer

International Deal Gateway (“IDG”) has been paid by Gemina Laboratories Ltd. (“Gemina Labs”) to provide various marketing and awareness services including posting content and conducting interviews on or through our platform and e-mail subscriber list. We do not own any securities of Gemina Labs. You should not make any investment decisions based on our communications.

The information contained herein relating to Gemina Labs has been prepared by or on behalf of Gemina Labs and the information regarding Gemina Labs is being provided to you by IDG at the direction of, and on behalf of Gemina Labs.

We are NOT securities dealers or brokers, investment advisors or financial advisors, and you should not rely on the information herein as investment advice. If you are seeking personal investment advice, please contact a qualified and registered broker, investment advisor or financial advisor.

At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. By using our website or platform you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.

We do not provide personalized or individualized investment advice or advice that is tailored to the needs of any particular recipient. Any information provided as part of the services is impersonal and not specific to any person’s investment needs. You acknowledge and agree that no content published or otherwise provided as part of any service constitutes a personalized recommendation or advice regarding the suitability of, or advisability of investing in, purchasing or selling any particular investment, security, portfolio, commodity, transaction or investment strategy. To the extent that any of the content may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person.

This content (including interviews) may include certain statements that constitute “forward-looking information or statements” and readers and viewers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. There are risks and other factors that could cause actual results and events to vary significantly.

The content disclosed herein is intended to highlight Gemina Labs for your further investigation; this is not a stock recommendation or constitute an offer or sale of the referenced securities. The securities of Gemina Labs may be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the company’s SEDAR and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR and SEC filings, company websites, and other publicly available sources. The information in our website / media webpage is believed to be accurate and correct and we have asked Gemina Labs to review the contents as it relates to them, but has not been independently verified and is not guaranteed to be correct.

This email does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America.

Forward-looking statements

Certain statements in this press release constitute “forward looking” statements that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, objectives or achievements of Gemina Labs, or industry results, to be materially different from any future results, performance, objectives, or achievements expressed or implied by such forward looking statements. When used in this press release, words such as “may”, “would”, “could”, “will”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan”, and other similar expressions are intended to identify forward-looking statements. These statements reflect Gemina Labs’ current views regarding future events and operating performance, are based on information currently available to Gemina Labs, and speak only as of the date of this press release.

These forward-looking statements involve a number of risks, uncertainties and assumptions and should not be read as guarantees that future performance or results will be achieved. Many factors could cause the actual results, performance, objectives, or achievements of Gemina Labs to be materially different from any future results, performance, objectives, or achievements that may be expressed or implied by such forward looking statements. Additional factors are discussed under the headings “Liquidity and capital resources” and “Risks and Uncertainties” in Gemina Labs management’s discussion and analysis, annual information form, and other publicly available disclosure documents, as filed by Gemina Labs on SEDAR (www.sedar.com).

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described in this presentation as intended, planned, anticipated, believed, estimated, or expected. Unless required by applicable securities law, Gemina Labs does not intend and does not assume any obligation to update these forward-looking statements.